IN8BIO, Inc. INAB

Healthcare Biotechnology

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

NDAQ:INAB - Post by User

IN8BIO, Inc.

<< Previous

Bullboard Posts

Post by whytestockson Jun 05, 2023 7:15pm

81 Views

Post# 35481437

IN8bio Announces Positive INB-200 Phase 1 Data Update in Gli

JUST IN: $INAB IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses remaining progression-free at 23.5 and 19.4 months, respectively. INB-200 continues to exhibit a manageable safety profile with minimal toxicities ...INAB - IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

<< Previous

Bullboard Posts

Canopy Growth prepares for U.S. expansion with new acquisitions